LON:STX - Shield Therapeutics Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: GBX 0
Forecasted Upside: -100.00 %
Number of Analysts: 2
Breakdown:
0 Sell Ratings
0 Hold Ratings
2 Buy Ratings
0 Strong Buy Ratings

GBX 55.49 As of 06/24/2021 05:36 PM ET

▲ +0.485 (0.88%)

1 month | 3 months | 12 months

Get New Shield Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for STX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STX

GBX 0

▼ -100.00% Downside Potential

This price target is based on 2 analysts offering 12 month price targets for Shield Therapeutics in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 55.49.

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Shield Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/1/2020

0 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/31/2020

0 strong buy ratings
2 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/29/2020

0 strong buy ratings
2 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/27/2020

0 strong buy ratings
2 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/26/2020

0 strong buy ratings
1 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/26/2021

0 strong buy ratings
2 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/25/2021

0 strong buy ratings
2 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/24/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target
5/18/2021	Peel Hunt	Reiterated Rating	Buy
5/18/2021	Peel Hunt	Reiterated Rating	Buy
7/16/2020	Peel Hunt	Reiterated Rating	Buy
7/2/2020	Peel Hunt	Reiterated Rating	Buy
6/3/2020	Peel Hunt	Reiterated Rating	Buy
5/21/2020	Peel Hunt	Reiterated Rating	Buy
5/21/2020	FinnCap	Reiterated Rating	Corporate
5/1/2020	Peel Hunt	Reiterated Rating	Buy
5/1/2020	FinnCap	Reiterated Rating	Corporate
4/22/2020	Peel Hunt	Reiterated Rating	Buy
4/22/2020	FinnCap	Reiterated Rating	Corporate
4/7/2020	Peel Hunt	Reiterated Rating	Buy
3/17/2020	Peel Hunt	Reiterated Rating	Buy
3/5/2020	Peel Hunt	Reiterated Rating	Buy
2/5/2020	Peel Hunt	Reiterated Rating	Buy
1/27/2020	Peel Hunt	Reiterated Rating	Buy
1/27/2020	FinnCap	Reiterated Rating	Corporate
1/8/2020	Peel Hunt	Reiterated Rating	Buy	GBX 200
1/8/2020	Peel Hunt	Reiterated Rating	Buy	GBX 200
12/5/2019	Peel Hunt	Reiterated Rating	Buy
11/4/2019	Peel Hunt	Reiterated Rating	Buy
10/23/2019	FinnCap	Reiterated Rating	Corporate
10/22/2019	Peel Hunt	Reiterated Rating	Buy
10/2/2019	Peel Hunt	Reiterated Rating	Buy	GBX 200
10/2/2019	Peel Hunt	Reiterated Rating	Buy	GBX 200
9/2/2019	Peel Hunt	Reiterated Rating	Buy
8/7/2019	Peel Hunt	Reiterated Rating	Buy
8/7/2019	FinnCap	Reiterated Rating	Corporate
8/1/2019	Peel Hunt	Reiterated Rating	Buy
7/26/2019	FinnCap	Reiterated Rating	Corporate
7/22/2019	Peel Hunt	Reiterated Rating	Buy	GBX 88 ➝ GBX 200
7/15/2019	Peel Hunt	Reiterated Rating	Buy
7/3/2019	Peel Hunt	Reiterated Rating	Buy
6/3/2019	FinnCap	Reiterated Rating	Corporate
6/3/2019	Peel Hunt	Reiterated Rating	Buy
5/14/2019	FinnCap	Initiated Coverage	Corporate	GBX 200
5/2/2019	Peel Hunt	Reiterated Rating	Buy
4/24/2019	Peel Hunt	Reiterated Rating	Buy
4/3/2019	Liberum Capital	Reiterated Rating	Buy
4/2/2019	Peel Hunt	Reiterated Rating	Buy
3/15/2019	Liberum Capital	Reiterated Rating	Buy
3/12/2019	Peel Hunt	Boost Price Target	Buy	GBX 70 ➝ GBX 88
3/4/2019	Peel Hunt	Reiterated Rating	Buy
3/4/2019	Liberum Capital	Reiterated Rating	Buy
2/19/2019	Liberum Capital	Boost Price Target	Buy	GBX 80 ➝ GBX 116
1/29/2019	Liberum Capital	Reiterated Rating	Buy
1/29/2019	Peel Hunt	Reiterated Rating	Buy
1/22/2019	Liberum Capital	Reiterated Rating	Buy
1/22/2019	Peel Hunt	Reiterated Rating	Buy
1/7/2019	Peel Hunt	Reiterated Rating	Buy
12/13/2018	Peel Hunt	Reiterated Rating	Buy
12/4/2018	Liberum Capital	Reiterated Rating	Buy
12/4/2018	Peel Hunt	Reiterated Rating	Buy
11/1/2018	Peel Hunt	Reiterated Rating	Buy
10/2/2018	Peel Hunt	Reiterated Rating	Buy
10/2/2018	Liberum Capital	Reiterated Rating	Buy
9/24/2018	Peel Hunt	Reiterated Rating	Buy	GBX 70
9/19/2018	Liberum Capital	Reiterated Rating	Under Review
9/4/2018	Peel Hunt	Reiterated Rating	Under Review
8/1/2018	Peel Hunt	Reiterated Rating	Under Review
7/23/2018	Liberum Capital	Reiterated Rating	Under Review
7/23/2018	Peel Hunt	Reiterated Rating	Under Review
6/28/2018	Peel Hunt	Reiterated Rating	Under Review
6/14/2018	Peel Hunt	Reiterated Rating	Under Review
5/31/2018	Peel Hunt	Reiterated Rating	Under Review
4/6/2018	Peel Hunt	Reiterated Rating	Under Review
4/6/2018	Liberum Capital	Reiterated Rating	Under Review
3/27/2018	Peel Hunt	Reiterated Rating	Under Review
3/16/2018	Peel Hunt	Reiterated Rating	Under Review
3/16/2018	Liberum Capital	Reiterated Rating	Under Review
2/22/2018	Liberum Capital	Reiterated Rating	Under Review
2/22/2018	Peel Hunt	Reiterated Rating	Under Review
2/5/2018	Liberum Capital	Reiterated Rating	Under Review
2/1/2018	Peel Hunt	Reiterated Rating	Buy	GBX 220
11/21/2017	FinnCap	Reiterated Rating	Buy	GBX 265
11/8/2017	Peel Hunt	Reiterated Rating	Buy	GBX 220
10/31/2017	Peel Hunt	Reiterated Rating	Buy	GBX 220
10/10/2017	Liberum Capital	Reiterated Rating	Buy	GBX 245
9/22/2017	FinnCap	Lower Price Target	Buy	GBX 270 ➝ GBX 265
9/20/2017	Peel Hunt	Reiterated Rating	Buy	GBX 220
9/20/2017	Liberum Capital	Reiterated Rating	Buy	GBX 245
9/14/2017	FinnCap	Reiterated Rating	Buy	GBX 270
9/14/2017	Liberum Capital	Reiterated Rating	Buy	GBX 245
9/7/2017	FinnCap	Initiated Coverage	Buy	GBX 270
9/6/2017	Liberum Capital	Reiterated Rating	Buy	GBX 245
7/6/2017	Peel Hunt	Reiterated Rating	Buy	GBX 220
6/22/2017	Liberum Capital	Reiterated Rating	Buy	GBX 245
4/25/2017	Liberum Capital	Reiterated Rating	Buy	GBX 245
4/4/2017	Liberum Capital	Lower Price Target	Buy	GBX 310 ➝ GBX 245
3/13/2017	Liberum Capital	Reiterated Rating	Buy	GBX 310
1/6/2017	Canaccord Genuity	Reiterated Rating	Buy	GBX 241
1/6/2017	Liberum Capital	Reiterated Rating	Buy	GBX 310
9/20/2016	Canaccord Genuity	Boost Price Target	Buy	GBX 235 ➝ GBX 241
9/20/2016	Liberum Capital	Reiterated Rating	Buy	GBX 310
8/11/2016	Canaccord Genuity	Reiterated Rating	Buy	GBX 235
7/18/2016	Canaccord Genuity	Initiated Coverage	Buy	GBX 235

(Data available from 6/24/2016 forward)

Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of late-stage pharmaceuticals to treat unmet medical needs. The company's lead product is Ferric Maltol, marketed in the European Union as Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anaemia in adults. It also develops PT20, a novel therapy that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease; PT30 to treat hypo-allergenic IV iron therapy; and PT40, the first generic version of iron sucrose. The company was founded in 2008 and is based in Gateshead, the United Kingdom.

Today's Range

Now: GBX 55.49

54.43

50 Day Range

MA: GBX 52.70

52 Week Range

Now: GBX 55.49

153

Volume

2,442,735 shs

Average Volume

1,603,514 shs

Market Capitalization

£119.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Shield Therapeutics?

The following sell-side analysts have issued reports on Shield Therapeutics in the last twelve months: Peel Hunt, and Peel Hunt LLP.
View the latest analyst ratings for STX.

What is the current price target for Shield Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Shield Therapeutics in the last year. has the lowest price target set, forecasting a price of £100,000 for Shield Therapeutics in the next year.
View the latest price targets for STX.

What is the current consensus analyst rating for Shield Therapeutics?

Shield Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe STX will outperform the market and that investors should add to their positions of Shield Therapeutics.
View the latest ratings for STX.

What other companies compete with Shield Therapeutics?

Other companies that are similar to Shield Therapeutics include Benchmark, Amryt Pharma, The Supreme Cannabis, ICC Labs, The Green Organic Dutchman, ESSA Pharma, Venture Life Group, Science in Sport, Diurnal Group, WeedMD, Delta 9 Cannabis, The Flowr, BioSyent, Acerus Pharmaceuticals and Cipher Pharmaceuticals.

How do I contact Shield Therapeutics' investor relations team?

Shield Therapeutics' physical mailing address is 3rd Fl Baltic Business Quarters, Abbott's Hill, GATESHEAD, NE8 3D, United Kingdom. The company's listed phone number is +44-191-5118500. The official website for Shield Therapeutics is www.shieldtherapeutics.com.